Enliven Therapeutics Inc.
ELVN | NASDAQ
$47.83
-$1.04 (-2.13%)
Sep 22, 2026, 12:00 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -8.42 | -11.90 | -6.89 | -2.71 | -2.84 | -20.46 |
PEG Ratio | 2.65 | 1.99 | 0.10 | -0.03 | 0.11 | 0.99 |
PS Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
PB Ratio | 1.90 | 3.42 | 2 | -1.33 | 0.66 | 4.59 |
P/FCF Ratio | -12.38 | -14.46 | -8.01 | -3.13 | -3.64 | -43.07 |
P/OCF Ratio | -12.41 | -14.47 | -8.03 | -3.19 | -3.68 | -45.40 |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | 0 | n/a | 0 | 0 | 0 | n/a |
Quick Ratio | 28.66 | 19.99 | 10.28 | 8 | 19.24 | 14.47 |
Current Ratio | 28.66 | 19.99 | 10.28 | 8 | 19.24 | 14.47 |
Asset Turnover | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -22.56% | -28.73% | -29.11% | 49.02% | -23.15% | -22.46% |
Return on Assets | -21.78% | -27.33% | -26.33% | -45.21% | -21.83% | -20.88% |
Return on Invested Capital | -26.01% | -33.74% | -33.91% | -52.49% | -22.98% | -11.01% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Margin | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove ELVN